Patents Assigned to Universite de Tours
  • Publication number: 20240424086
    Abstract: A fusion protein including fragments of the spike protein and of the nucleoprotein of a coronavirus. Also a vaccine, a composition, a pharmaceutical composition, or a diagnostic kit including the fusion protein, a method for diagnosing an infection by a coronavirus and to a method for preventing or treating a coronavirus infection based on the use of the fusion protein.
    Type: Application
    Filed: September 7, 2022
    Publication date: December 26, 2024
    Applicants: UNIVERSITE DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE), UNIVERSITÉ DE LILLE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE
    Inventors: Nicolas AUBREY, Fanny BOURSIN, Zineb LAKHRIF, Isabelle DIMIER-POISSON, Mathieu EPARDAUD, Rodolphe CARPENTIER, Antoine TOUZE, Marie-Noëlle MEVELEC
  • Patent number: 12123058
    Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 22, 2024
    Assignees: SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
    Inventors: Olivier Cussenot, Aurélie Kamoun, Aurélien De Reynies, Géraldine Cancel-Tassin, Gaëlle Fromont-Hankard
  • Patent number: 12115393
    Abstract: The present invention relates the field of ultrasound and neurostimulation. The inventors have shown that using ultrasound neurostimulation with specific parameters provides similar or better effects that fluoxetine administration in depression. Such assessment was made in unpredictable chronic mild stress model in mouse. The proposed use also provides with positive effects in other cases, such as modulating emotion or attenuating anxiety-related behaviours (stress notably).
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: October 15, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE TOURS
    Inventors: Ayache Bouakaz, Catherine Belzung
  • Patent number: 12085630
    Abstract: The invention relates to quality control devices and methods for magnetic resonance imaging (MRI) systems, more particularly for medical imaging applications. An example is stereotactic surgery where MRI images are combined with X-ray images to accurately locate a target in a subject. A test device (1), and an associated method using said test object, are used to easily detect a faulty calibration or a malfunction of an MRI device. The test device includes: a hermetically sealable hollow body (20) having a substantially cylindrical shape, a support frame (22) configured to be removably inserted in the hollow body and defining a target region (V22) having a substantially cylindrical shape; and a plurality of target objects (24) made of a material visible on X-ray images and MRI images said target objects being arranged in the target region and being attached to the support frame.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: September 10, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS
    Inventors: Christophe Destrieux, Laurent Barantin
  • Patent number: 11932638
    Abstract: The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R? is an -A1-Cy1 group, or R is an -A1-Cy1 group and R? is an R1 group, R1 particularly being H or (C1-C6)alkyl group; A1 being an —NH— radical or —NH—CH2— radical; Cy1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 19, 2024
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE, UNIVERSITE D'ORLEANS, UNIVERSITE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE (INSERM), CHU NANTES
    Inventors: Sylvain Routier, Frédéric Buron, Nuno Rodrigues, Gaëlle Fourriere-Grandclaude, Christophe Vandier, Aurélie Chantome, Marie Potier-Cartereau, Maxime Gueguinou, Séverine Marionneau-Lambot
  • Publication number: 20230372416
    Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 23, 2023
    Applicants: UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Nathalie HEUZE-VOURC'H, Thomas SECHER, Muriel THOMAS
  • Publication number: 20230287031
    Abstract: New glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. Also, pharmaceutical compositions including compounds of Formula (I) for use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 14, 2023
    Applicants: UNIVERSITÉ DE BRETAGNE OCCIDENTALE, UNIVERSITÉ DE TOURS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Paul Alain JAFFRES, Hélène COUTHON, Charlotte SEVRAIN, Alicia BAUDUIN, Christophe VANDIER, Aurélie CHANTÖME, Delphine FONTAINE
  • Publication number: 20230236122
    Abstract: A method for determining the risk of developing a blood disorder, which includes the steps of: exposing a biological sample from an individual to radiation to obtain a spectrum characteristic of the sample, the spectrum being processed in order to obtain a spectral signature; comparing the spectral signature obtained with one or more reference spectral signatures; and concluding, if the spectral signature of the individual is significantly different from control spectral signatures, that the individual is likely to develop a blood disorder, and, if not, that the individual is not likely to develop a blood disorder.
    Type: Application
    Filed: May 24, 2021
    Publication date: July 27, 2023
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, UNIVERSITÉ DE TOURS
    Inventors: Olivier HERAULT, Olivier SIRE
  • Publication number: 20230203197
    Abstract: New human therapeutic monoclonal antibodies, which are directed against neutrophil proteinase 3. The monoclonal antibodies are specifically directed against a conformational epitope of the neutrophil proteinase 3 and are capable of inhibiting by at least 30% the production for reactive oxygen derivatives by neutrophils. Also, a pharmaceutical composition including as an active substance at least the monoclonal antibody, and a method for early treatment and/or prevention of relapse of granulomatosis with polyangiitis, which includes the administration of the pharmaceutical composition.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 29, 2023
    Applicants: UNIVERSITE DE TOUR, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roxane LEMOINE, Cyrille HOARAU, Eric MORELLO, Brice KORKMAZ, Yann GALLAIS
  • Publication number: 20220396612
    Abstract: A new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 15, 2022
    Applicants: UNIVERSITÉ DE TOURS, UNIVERSITE DE PICARDIE JULES VERNE, CENTRE HOSPITALIER UNIVERSITAIRE AMIENS-PICARDIE
    Inventors: Antoine TOUZE, Pauline GABORIAUD, Etienne BROCHOT
  • Patent number: 11504094
    Abstract: An apparatus and a method for contrast-enhanced ultrasound (CEUS) including use of a fluid dynamics model for the analysis of dynamic contrast-enhanced ultrasound (DCEUS).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 22, 2022
    Assignees: (INSERM) INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE TOURS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUX, INSTITUT POLYTECHNIQUE DE BORDEAUX (IPB)
    Inventors: Baudouin Denis de Senneville, Franck Perrotin, Jean-Michel Escoffre, Ayache Bouakaz
  • Publication number: 20220233607
    Abstract: A strain of an Apicomplexa of the family Sarcocystidae, wherein the strain is replicative and expresses one or more heterologous protein(s) selected from the group including therapeutic proteins, antigens, recombinant surface receptor or combinations thereof, and wherein the strain is selected from the group including Toxoplasma gondii and Neospora caninium. Also, the use of the strain for preventing or treating cancers or infectious diseases in a subject in need thereof.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 28, 2022
    Applicants: UNIVERSITÉ DE TOURS, KYMERIS THERAPEUTICS INC., INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L' ALIMENTATION ET L'ENVIRONNEMENT
    Inventors: Isabelle DIMIER-POISSON, Marie-Noëlle MEVELEC, Anne DI TOMMASO, Nicolas AUBREY, Louis LANTIER, Gordon LEE
  • Patent number: 11340211
    Abstract: The invention relates to an in vitro method for evaluating digestive efficiency (DE) of poultry, in particular chickens, by measuring color of a sample of liquid fraction of blood of said poultry.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 24, 2022
    Assignees: UNIVERSITE DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR LAGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
    Inventors: Sandrine Grasteau, Elisabeth Duval, Stéphane Beauclercq
  • Patent number: 10961588
    Abstract: This invention relates to an in vitro method for prognosis of the response to a chemotherapy of an individual suffering from chronic myeloid leukemia, comprising a. a step of measuring the expression level of at least one subgroup of genes chosen from a group of genes, b. a comparing step, and c. a step of determining a score S such that—if S is less than 1, said individual will have more than a 40% chance of responding to the chemotherapy, and—if S is greater than or equal to 1, said individual will have less than a 40% chance of responding to the chemotherapy.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: March 30, 2021
    Assignee: UNIVERSITÉ DE TOURS
    Inventor: Olivier Herault
  • Publication number: 20210040563
    Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Applicants: SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
    Inventors: Olivier CUSSENOT, Aurélie KAMOUN, Aurélien DE REYNIES, Géraldine CANCEL-TASSIN, Gaëlle FROMONT-HANKARD
  • Patent number: 10906900
    Abstract: The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: February 2, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS, UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Sylvain Routier, Franck Suzenet, Sylvie Chalon, Frederic Buron, Johnny Vercouillie, Ronald Melki, Liliana Boiaryna, Denis Guilloteau, Laura Pieri
  • Patent number: 10814079
    Abstract: A nasal fluid-spray device having: a reservoir containing at least one dose (D) of fluid; and a dispenser system that, each time the device is actuated, sprays a dose (D) of fluid through a spray orifice, generating a spray that extends axially from the spray orifice. The device further includes a generator system for generating a secondary flow, which generator system is actuated simultaneously with the dispenser system, the secondary flow generator system having a secondary flow channel provided with an outlet orifice, the outlet orifice arranged downstream from the spray orifice, and the secondary flow extending from the outlet orifice along an axis (B) that forms an angle (?) relative to the axis (A) of the spray and that intersects the axis (A), thereby deforming and/or deflecting the spray.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: October 27, 2020
    Assignee: UNIVERSITE DE TOURS
    Inventors: Mirvatte Francis, Laurent Vecellio-None
  • Publication number: 20200330568
    Abstract: The present invention relates to a strain of Neospora caninum for use in treating cancer or infectious diseases.
    Type: Application
    Filed: July 1, 2020
    Publication date: October 22, 2020
    Applicants: UNIVERSITÉ DE TOURS, KYMERIS THERAPEUTICS INC., Institut national de recherche pour l'agriculture, l'alimentation et l'environnement
    Inventors: Isabelle DIMIER-POISSON, Marie-Noëlle MEVELEC, Céline DUCOURNAU, Nathalie MOIRE, Richard MCCRAE
  • Patent number: 10766930
    Abstract: An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 8, 2020
    Assignees: UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE—INSERM
    Inventors: Christophe Hourioux, Romuald Patient, Elodie Beaumont, Philippe Roingeard
  • Patent number: 10736947
    Abstract: The present invention relates to a strain of Neospora caninum for use in treating cancer or infectious diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: August 11, 2020
    Assignees: UNIVERSITÉ DE TOURS, KYMERIS THERAPUETICS INC., Institut national de recherche pour l' agriculture, l' alimentation et l'environneement
    Inventors: Isabelle Dimier-Poisson, Marie-Noëlle Mevelec, Céline Ducournau, Nathalie Moire, Richard McCrae